XILIO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 USD | +7.92% |
|
-5.22% | +98.18% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 437.3 | 73.73 | 15.14 | 40.23 | - | - |
| Enterprise Value (EV) 1 | 249 | -36.83 | 15.14 | -156 | -261.4 | -220.1 |
| P/E ratio | -1.18 x | -0.84 x | -0.2 x | -0.67 x | -0.9 x | -0.69 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 5.36 x | 2.15 x | 12.9 x |
| EV / Revenue | - | - | - | -20.8 x | -13.9 x | -70.4 x |
| EV / EBITDA | -3.39 x | 0.42 x | - | 2.82 x | 6.75 x | 2.71 x |
| EV / FCF | -3,125,977 x | 474,646 x | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - |
| Price to Book | 2.37 x | 0.7 x | - | 0.22 x | 0.16 x | 0.2 x |
| Nbr of stocks (in thousands) | 27,333 | 27,407 | 27,529 | 36,907 | - | - |
| Reference price 2 | 16.00 | 2.690 | 0.5500 | 1.090 | 1.090 | 1.090 |
| Announcement Date | 3/1/22 | 3/2/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 7.5 | 18.75 | 3.125 |
| EBITDA 1 | - | -73.54 | -87.3 | - | -55.29 | -38.75 | -81.12 |
| EBIT 1 | - | -75.04 | -89.15 | -79.13 | -69.73 | -73.34 | -109.4 |
| Operating Margin | - | - | - | - | -929.73% | -391.16% | -3,499.49% |
| Earnings before Tax (EBT) 1 | - | -75.8 | -88.22 | -76.4 | -67.37 | -72.7 | -123.7 |
| Net income 1 | -55.22 | -75.8 | -88.22 | -76.4 | -67.37 | -72.7 | -123.7 |
| Net margin | - | - | - | - | -898.31% | -387.72% | -3,958.51% |
| EPS 2 | -11.10 | -13.52 | -3.220 | -2.780 | -1.637 | -1.213 | -1.570 |
| Free Cash Flow | - | -79.65 | -77.59 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/24/21 | 3/1/22 | 3/2/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - |
| EBITDA 1 | -15.26 | -19.16 | -20.78 | -24.11 | -19.73 | -22.68 | -23.03 | -19.62 | -16.9 | - | 12.31 | -18.25 | -17.03 | -17.04 | -18.45 |
| EBIT 1 | -15.96 | -19.56 | -21.22 | -24.55 | -20.21 | -23.17 | -23.53 | -20.12 | -17.36 | -18.13 | -2.695 | -19.47 | -19.84 | -21.34 | -18.95 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | -26.95% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -16.25 | -19.7 | -21.35 | -24.61 | -19.79 | -22.47 | -22.65 | -19.36 | -16.75 | -17.66 | -0.405 | -19.42 | -19.8 | -21.3 | -18.95 |
| Net income 1 | -16.25 | -19.7 | -21.35 | -24.61 | -19.79 | -22.47 | -22.65 | -19.36 | -16.75 | -17.66 | -0.4035 | -19.42 | -19.79 | -21.29 | -18.95 |
| Net margin | - | - | - | - | - | - | - | - | - | - | -4.04% | - | - | - | - |
| EPS 2 | -0.8830 | -0.9800 | -0.7800 | -0.9000 | -0.7200 | -0.8200 | -0.8300 | -0.7000 | -0.6100 | -0.6400 | -0.0750 | -0.4550 | -0.4750 | -0.5150 | -0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/2/21 | 3/1/22 | 5/12/22 | 8/9/22 | 11/9/22 | 3/2/23 | 5/9/23 | 8/14/23 | 11/9/23 | 4/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 188 | 111 | - | 196 | 302 | 260 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -79.7 | -77.6 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -148% | -60.6% | - | -65.2% | -31.9% | -24.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 6.750 | 3.860 | - | 4.960 | 6.730 | 5.540 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 1.87 | - | 0.8 | 1 | 1 |
| Capex / Sales | - | - | - | - | 10.67% | 5.33% | 32% |
| Announcement Date | 5/24/21 | 3/1/22 | 3/2/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.09
USD
Average target price
4.667
USD
Spread / Average Target
+328.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +98.18% | 40.23M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- XLO Stock
- Financials Xilio Therapeutics, Inc.
